Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Transferencia de genes para pacientes con enfermedad de células falciformes

28 de octubre de 2026 actualizado por: Children's Hospital Medical Center, Cincinnati

Transferencia de genes para pacientes con enfermedad de células falciformes utilizando un vector de lentivirus de gamma globina: un estudio piloto de fase 1/2 de etiqueta abierta

The purpose of this Phase 1/2 study is to determine the feasibility and safety of stem cell collection and gamma-globin gene transfer, and success of gene correction in subjects with sickle cell disease

Descripción general del estudio

Estado

Terminado

Intervención / Tratamiento

Descripción detallada

This study will assess the feasibility, safety and efficacy of gene transfer using ARU-1801 (CD34+ cells transduced with the gamma-globin lentiviral vector). Gene transfer will occur ex-vivo into CD34+ enriched human bone marrow or plerixafor-mobilized peripheral blood hematopoietic stem cells (HSC) collected from subjects with severe sickle cell disease (SCD). Subjects will undergo reduced intensity chemotherapy conditioning with single-dose melphalan to facilitate engraftment of ex-vivo ARU-1801 via IV infusion. Subjects will return to the study site at regular intervals for follow-up for 2 years after the ARU-1801 infusion. It is anticipated that a separate long-term follow-up (LTFU) clinical study will be initiated, in which all subjects completing the 2 year study visit will be asked to consent and enroll, and will followed for a further 13 years.

Tipo de estudio

Intervencionista

Inscripción (Actual)

7

Fase

  • Fase 2
  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45229
        • Cincinnati Children's Hospital Medical Center

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 45 años (Adulto)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria

  • Signed informed consent form.

  • Has confirmed diagnosis of sickle cell disease (SCD)

  • Has severe sickle cell disease, defined as one or more of the following:

    1. Minimum of two episodes of clinically diagnosed acute chest syndrome (ACS) requiring hospital admission, or one life threatening episode of ACS requiring intensive care unit (ICU) admission for exchange transfusion and/or intubation, or frequent ACS episodes which necessitate treatment with chronic transfusion therapy.
    2. Frequent painful vaso-occlusive episodes (VOEs) which significantly interfere with normal life activities, defined as a history of 2 or more severe acute sickle pain events per year requiring additional treatment at a medical facility outside of home pain management over the preceding 2-year period prior to study enrollment, or that necessitate chronic transfusion therapy.
    3. Subjects on chronic transfusion therapy for severe disease symptoms other than those listed above, and which interfere with normal life activities.
  • Has failed hydroxyurea therapy, was unable to tolerate hydroxyurea therapy, or has actively made the choice to not take the recommended daily hydroxyurea advised for severe disease (Note: must be off hydroxyurea therapy for 2 months prior to stem cell collection). If refusing hydroxyurea, the subject must document that they have been educated about the benefits and continue to refuse the treatment. Patients placed on chronic transfusion therapy instead of hydroxyurea for severe disease are eligible. Subjects unable to take hydroxyurea due to financial or safety monitoring constraints are eligible.

  • Has adequate functional status and organ function as determined at Screening.

Exclusion Criteria

  • Female subjects who are pregnant or lactating/breastfeeding.
  • Female subjects who are not surgically sterile, postmenopausal or who refuse to practice effective method of birth control as determined by the Investigator for one year after receiving the study drug. Women must also agree not to breastfeed for 1 year after receiving the study drug.
  • Any participant of reproductive potential who refuses to agree to use an appropriate contraceptive method determined by the Investigator, for 1 year after receiving the study drug.
  • Patients with an active malignant disease or receiving treatment for any type of cancer (except squamous cell carcinoma, basal cell carcinoma, or carcinoma in situ of the skin).
  • Current diagnosis or history of hepatitis B, hepatitis C, or HIV.
  • Has received another study drug within 30 days, or 5 half-lives of the last dose (whichever is longer), prior to screening.
  • Has severe obstruction, restriction or diffusion defect on pulmonary function tests.
  • Has uncontrolled bacterial, viral or fungal infections within 1 month prior to starting the conditioning part of the study. Subjects with fever should wait for symptoms to resolve before starting the conditioning part of the study.
  • Has a history of stroke or is at moderate to high risk of primary stroke (eg receiving chronic transfusions or hydroxyurea for primary prevention of stroke; has severe cerebral vasculopathy defined as moderate stenosis in >2 arterial segments; and/or has sever stenosis/occlusion in ≤2 segments in the polygon of Willis or presence of Moyamoya-like disease).
  • Patients with alpha thalassemia sickle cell disease.
  • Has previous liver biopsy showing cirrhosis, bridging hepatic fibrosis, or active hepatitis; or has received chronic transfusions and has previous evidence of iron overload and evidence of liver fibrosis by noninvasive liver imaging.
  • Has a matched sibling donor, unless the subject has declined this option or this option is not feasible. Documentation must be included as part of the informed consent process for subjects who decline this option.
  • Has a known hypersensitivity to any study treatments (e.g. melphalan, plerixafor).

Other protocol-defined inclusion-exclusion criteria may apply.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Cuidados de apoyo
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: ARU-1801

Autologous CD34+ hematopoietic stem cells transduced ex-vivo with gamma-globin lentiviral vector. Administered via IV infusion.

Autologous CD34+ hematopoietic stem cells transduced ex-vivo with a gamma-globin lentiviral vector

  • Subjects with sickle cell anemia will undergo hematopoietic stem cell procurement by bone marrow harvest or apheresis after mobilization with plerixafor
  • Reduced intensity chemotherapy conditioning with single dose melphalan will be used to facilitate engraftment of ex-vivo transduced cells.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of Participants With Grade 3 Allergic Reaction
Periodo de tiempo: From infusion (Day 0) to 30 days post-infusion

Number of Participants with Grade 3 allergic reaction associated with infusion of transduced cell product

From infusion (Day 0) to 30 days post-infusion
Number of Participants Grade 4 Infection
Periodo de tiempo: From infusion (Day 0) to 30 days post-infusion

Number of Grade 4 infection following infusion of transduced cell product uncontrolled for ≥14 days

From infusion (Day 0) to 30 days post-infusion
Total Number of Grade 4 Neutropenia
Periodo de tiempo: From date of chemotherapy clearance visit to to 30 days post-infusion

Number of participants with Grade 4 neutropenia lasting >1 month following melphalan

From date of chemotherapy clearance visit to to 30 days post-infusion
Number of Participants With Grade 3 or 4 Toxicity Events
Periodo de tiempo: From infusion (Day 0) to 30 days post-infusion

Number of Participants with Grade 3 or 4 organ toxicity attributable to study procedures

From infusion (Day 0) to 30 days post-infusion
Total Number of Adverse Events (AEs) and Serious Adverse Events (SAE)
Periodo de tiempo: From infusion (Day 0) to 30 days post-infusion
From infusion (Day 0) to 30 days post-infusion
Number of Death Due to Study Procedures
Periodo de tiempo: From screening to the end of study, and up to 12 months.
From screening to the end of study, and up to 12 months.
Number of Hematological Malignancy
Periodo de tiempo: From infusion (Day 0) to end of study, up to 12 months

Number of hematological malignancy due to vector insertion

From infusion (Day 0) to end of study, up to 12 months
Number of Hematological Cancer
Periodo de tiempo: From infusion (Day 0) to end of study, up to 12 months.

Number of hematological cancer related to investigational product or study medications/procedures

From infusion (Day 0) to end of study, up to 12 months.
Time to Neutrophil Recovery
Periodo de tiempo: From infusion (Day 0) to end of study, up to 12 months.

Duration of neutropenia following conditioning (defined as the time from first measurement where absolute neutrophil count (ANC) < 500 cells/µL to first of 3 consecutive absolute neutrophil count measurements on 3 consecutive days with ANC ≥500 cells/µL)

From infusion (Day 0) to end of study, up to 12 months.
Time to Platelet Recovery
Periodo de tiempo: From infusion (Day 0) to end of study, up to 12 months.

Duration of thrombocytopenia following conditioning (defined as the time from first measurement where platelet count < 50,000 cells/µL to the first of 3 consecutive platelet counts on 3 consecutive days > 50,000 cells/µL and independent of platelet transfusion for ≥7 days consecutive days)

From infusion (Day 0) to end of study, up to 12 months.
≥8x10⁶kg Viable CD34+ Cells
Periodo de tiempo: Date of Enrollment to Infusion (day 0).

Number of subjects with a total number of CD34+ cells recovered from all collections combined (mobilized peripheral blood and bone marrow) of at least ≥8x10⁶kg viable CD34+ cells

Date of Enrollment to Infusion (day 0).
≥4x10⁶ CD34+ Cells/kg Body Weight Transduced
Periodo de tiempo: Date of Enrollment to Infusion (day 0).

Proportion of subjects for which a minimum of 4x10⁵ CD34+ cells/kg body weight from all collections combined have been successfully transduced

Date of Enrollment to Infusion (day 0).
Number of Subjects With Bone Marrow Aspirates With ≥1% Gene-marked Cells
Periodo de tiempo: Infusion (Day 0) to 1 year post infusion.

Number of subjects with bone marrow aspirates at 1-year post-infusion with ≥1% gene-marked cells

Infusion (Day 0) to 1 year post infusion.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of HBF^G16D
Periodo de tiempo: Infusion to 12 months post-infusion

Percentage of HBF^G16D relative to total Hemoglobin

Infusion to 12 months post-infusion
Change in Proportion of Antisickling/Sickling Hemoglobin
Periodo de tiempo: Enrollment to Month 24

Evaluation of the longitudinal change in the ratio of total antisickling hemoglobin fractions, comprising Fetal Hemoglobin (HbF), the gene-modified hemoglobin variant (HbFG16D), and Hemoglobin A2 (HbA2), relative to Sickling Hemoglobin (HbS). This outcome assesses the stable expression of the therapeutic transgene and the successful shift in the underlying hemoglobin profile post-infusion. Measurements will be performed using Capillary Zone Electrophoresis (CZE) to quantify the individual percentages of each hemoglobin fraction. The antisickling proportion is defined as the sum percentage: (HbF+HbFG16D+HbA2). This value will be compared between the baseline (pre-conditioning/pre-infusion) and the evaluable period through month 24 post-infusion to determine the sustained pancellular distribution of non-sickling hemoglobins. Higher values are considered a successful outcome.

Enrollment to Month 24
Percentage of F-retics (Fetal Hemoglobin Content in Reticulocytes)
Periodo de tiempo: Infusion to 12 months post-infusion

This measure quantifies the proportion of newly formed red blood cells (reticulocytes) containing detectable levels of fetal hemoglobin (HbF). Because reticulocytes reflect the most recent erythropoietic activity (the last 24-48 hours), this percentage serves as a real-time indicator of the induction of HbF at the erythroid precursor level. This is measured by flow cyctometry.

Infusion to 12 months post-infusion
Percent VCN at 6 Months
Periodo de tiempo: Infusion to 6 months post-infusion

This measure assesses the percentage of infusion product Vector copy number (VCN) at six months post-infusion in each patient. VCN analysis is performed on DNA from the white blood cell fraction using quantitative polymerase chain reaction (qPCR).

Infusion to 6 months post-infusion

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Silla de estudio: Stella M. Davies, MB BS, PhD, MRCP, Children's Hospital Medical Center, Cincinnati

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de julio de 2014

Finalización primaria (Actual)

31 de octubre de 2022

Finalización del estudio (Actual)

31 de octubre de 2022

Fechas de registro del estudio

Enviado por primera vez

30 de junio de 2014

Primero enviado que cumplió con los criterios de control de calidad

9 de julio de 2014

Publicado por primera vez (Estimado)

10 de julio de 2014

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

28 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir